Synergistic antitumor effect of bispecific CD19 × CD3 and CD19 × CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma

Journal of Immunology

Volumn 169, Issue 1, 2002, Pages 137-144

  Kipriyanov, Sergey M ^a   Cochlovius, Björn ^a   Schäfer, Holger J ^a   Moldenhauer, Gerhard ^a   Bähre, Alexandra ^a   Le Gall, Fabrice ^a   Knackmuss, Stefan ^a   Little, Melvyn ^a  

^a Affirmed Therapeutics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD16 ANTIGEN; CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CELL ISOLATION; CYTOLYSIS; DISSOCIATION; EFFECTOR CELL; HUMAN; HUMAN CELL; MOUSE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SCID MOUSE; TUMOR CELL; TUMOR REGRESSION;

EID: 0036644061     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.1.137     Document Type: Article

References (50)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
2. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends
3. Immunotherapeutic perspective for bispecific antibodies
4. Bispecific antibodies in cancer therapy
5. Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy
6. G19.4(αCD3) × B43(αCD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells
7. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies
8. Killing of autologous B-lineage malignancy using CD3 × CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma
9. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3 × CD19 bispecific antibody
10. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3 × CD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells
11. CD3 × CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma
12. Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cells
13. Immunotherapy of B-cell lymphoma with CD3 × 19 bispecific antibodies: Costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells
14. CD3 × CD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow
15. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
16. Treatment of human B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells
17. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 × CD19 tandem diabody, and CD28 costimulation
18. Locoregional treatment of low-grade B-cell lymphoma with CD3 × CD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation
19. Locoregional treatment of low-grade B-cell lymphoma with CD3 × CD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses
20. Generation of recombinant antibodies
21. Of mice and men: Hybridoma and recombinant antibodies
22. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody
23. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
24. Crystal structure of a diabody, a bivalent antibody fragment
25. High level secretion of a humanized bispecific diabody from Escherichia coli
26. Biology and clinical relevance of human natural killer cells
27. The biology of human natural killer-cell subsets
28. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody
29. A bispecific diabody that mediates natural killer cell cytotoxicity against xeno-transplanted human Hodgkin's tumors
30. Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay
31. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies
32. The JAM test: A simple assay for DNA fragmentation and cell death
33. Nonparametric estimation from incomplete observations
34. Statistical aspects of the analysis of data from retrospective studies of disease
35. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation
36. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo
37. Costimulatory regulation of T cell function
38. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis
39. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity
40. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies
41. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease
42. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human FcγRIII
43. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: Role of infusion schedule and costimulation with cytokines
44. Immune regulation: A critical link between NK cells and CTLs
45. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 × CD19
46. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: Stimulation of cytotoxic pathways in vivo
47. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2
48. A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: Implication for the intense tumor infiltration by T lymphocytes and macrophages
49. Role of chemokines in the biology of natural killer cells
50. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody